Immunotherapy / PD-1 inhibitorInvestigationalInvestigational
Dostarlimab
How it works
Blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Colorectal Cancer— All patients
Ovarian Cancer— PD-L1-positive
Efficacy
In clinical trials, Dostarlimab achieved complete responses in approximately 70% of patients with mismatch repair-deficient (dMMR) metastatic colorectal cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Dostarlimab in Stage II and III Colon Cancers with Deficient DNA Repair | Colorectal Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Modest Progression-Free Survival Benefit in Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | The primary endpoint was investigator-assessed progression-free survival (PFS) as per RECIST v1.1, with a median of 20.6 months in arm 3 versus 19.2 months in arm 2. | Source → |
| New Treatment Combination Shows Modest Activity in Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | The objective response rate was 17.1% (80% CI, 9.8 to 27.0), including one complete response (2.4%). | Source → |
| Dostarlimab Shows Promising Results in Advanced Rectal Cancer | Colorectal Cancer | phase-2 | 100% of patients achieved a clinical complete response. | Source → |
| Dostarlimab Shows Promise in Treating Various Cancers | Melanoma | phase-2 | Dostarlimab showed a 100% complete cure of patients with colorectal cancer. | Source → |
| Dostarlimab: A Treatment for Advanced Endometrial Cancer | Colorectal Cancer | phase-2 | A 100% remission rate was reported for rectal cancer. | Source → |
| Endometrial Cancer Patient Responds Well to Dostarlimab | Colorectal Cancer | preclinical | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.